LAURUSLABS

Laurus Labs Share Price

 

 

Invest in Laurus Labs with 3.3X leverage

Invest with MTF

Performance

  • Low
  • ₹956
  • High
  • ₹985
  • 52 Week Low
  • ₹512
  • 52 Week High
  • ₹1,141
  • Open Price₹985
  • Previous Close₹980
  • Volume1,009,240
  • 50 DMA₹1,013.17
  • 100 DMA₹974.03
  • 200 DMA₹880.58

Investment Returns

  • Over 1 Month -12.88%
  • Over 3 Month -1.95%
  • Over 6 Month + 11.93%
  • Over 1 Year + 57.52%

Smart Investing Starts Here Start SIP with Laurus Labs for Steady Growth!

Invest Now

Laurus Labs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 61.7
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 52,040
  • P/B Ratio
  • 10.8
  • Average True Range
  • 36.6
  • EPS
  • 15.62
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -19.05
  • RSI
  • 39.3
  • MFI
  • 21.03

Laurus Labs Financials

Laurus Labs Technicals

EMA & SMA

Current Price
₹963.95
-16.35 (-1.67%)
pointer
  • Bearish Moving Average 12
  • Bullish Moving Average 4
  • 20 Day
  • ₹1,003.24
  • 50 Day
  • ₹1,013.17
  • 100 Day
  • ₹974.03
  • 200 Day
  • ₹880.58

Resistance and Support

968.52 Pivot Speed
  • R3 1,009.43
  • R2 997.32
  • R1 980.63
  • S1 951.83
  • S2 939.72
  • S3 923.03

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Laurus Labs Ltd. is a leading pharmaceutical company specializing in the development and manufacture of Active Pharmaceutical Ingredients (APIs), focusing on anti-retrovirals, oncology, and cardiovascular treatments. It also provides contract development and manufacturing (CDMO) services globally.

Laurus Labs has an operating revenue of Rs. 6,721.63 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 9% is okay, ROE of 8% is fair but needs improvement. The company has a reasonable debt to equity of 14%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 13% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 76 which is a FAIR score but needs to improve its earnings, a RS Rating of 89 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at C which is evident from recent supply seen, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Laurus Labs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-01-23 Quarterly Results
2025-10-23 Quarterly Results & Interim Dividend
2025-07-25 Quarterly Results
2025-04-24 Audited Results & Interim Dividend
2025-01-24 Quarterly Results
Date Purpose Remarks
2025-10-31 INTERIM Rs.0.80 per share(40%)Interim Dividend
2025-05-09 INTERIM Rs.0.80 per share(40%)Second Interim Dividend
2024-11-06 INTERIM Rs.0.40 per share(20%)Interim Dividend
2024-05-08 INTERIM Rs.0.40 per share(20%)Interim Dividend
2023-11-02 INTERIM Rs.0.40 per share(20%)Interim Dividend
View Laurus Labs Dividend History Arrow

Laurus Labs F&O

Laurus Labs Shareholding Pattern

27.49%
9.49%
1.52%
26.52%
0%
22.64%
12.34%

Laurus Labs FAQs

Laurus Labs share price is ₹963 As on 05 February, 2026 | 18:30

The Market Cap of Laurus Labs is ₹52039.5 Cr As on 05 February, 2026 | 18:30

The P/E ratio of Laurus Labs is 61.7 As on 05 February, 2026 | 18:30

The PB ratio of Laurus Labs is 10.8 As on 05 February, 2026 | 18:30

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23